Randomized phase II study of nab-Paclitaxel (nab-PTX) plus Carboplatin(CBDCA) followed by maintenance nab-PTX or TS-1 plus CBDCA followed by maintenance TS-1 as first-line treatment in patients with stage IIIB/IV squamous cell carcinoma of the lung.
Phase of Trial: Phase II
Latest Information Update: 30 Oct 2018
Price : $35 *
At a glance
- Drugs Gimeracil/oteracil/tegafur (Primary) ; Paclitaxel (Primary) ; Carboplatin
- Indications Lung cancer; Squamous cell cancer
- Focus Therapeutic Use
- 24 Oct 2018 Status changed from recruiting to discontinued.
- 03 Mar 2014 New trial record